BACKGROUND: MicroRNA-130a (miR-130a) regulates angio-cellular dysregulation, atherosclerosis, and cardiocerebral injuries, serving as a biomarker for major adverse cardiovascular and cerebral events (MACCE) in several chronic diseases. However, its clinical application in patients with end-stage renal disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD), who are at a high risk of developing MACCE, has not been reported. Therefore, this study aimed to explore this aspect. METHODS: miR-130a expression in peripheral blood mononuclear cells obtained from 50 healthy controls (HCs) at recruitment and 257 ESRD patients undergoing CAPD at month (M)0, M12, M24, and M36 was determined by reverse transcription-quantitative polymerase chain reaction. ESRD patients undergoing CAPD were followed up until MACCE occurred or M36. Then, MACCE were recorded, and MACCE-free survival was calculated. RESULTS: miR-130a expression was significantly lower in ESRD patients undergoing CAPD than in HCs (p < 0.001). In addition, miR-130a expression significantly decreased from M0 to M36 in ESRD patients undergoing CAPD (p < 0.001). Moreover, miR-130a expression at M0, M12, and M24 was significantly lower in patients with MACCE than in those without MACCE (all p < 0.05). Furthermore, high miR-130a expression at M0, M12, and M36 was significantly correlated with prolonged MACCE-free survival in ESRD patients undergoing CAPD (all p < 0.05), and high miR-130a expression at M0 was an independent factor for improved MACCE-free survival (p = 0.015; hazard ratio (HR) (95% confidential interval): 0.456 (0.243-0.857)). CONCLUSION: miR-130a expression decreases continuously with disease progression in patients with ESRD undergoing CAPD. Additionally, this expression is negatively correlated with MACCE risk in these patients.
BACKGROUND: MicroRNA-130a (miR-130a) regulates angio-cellular dysregulation, atherosclerosis, and cardiocerebral injuries, serving as a biomarker for major adverse cardiovascular and cerebral events (MACCE) in several chronic diseases. However, its clinical application in patients with end-stage renal disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD), who are at a high risk of developing MACCE, has not been reported. Therefore, this study aimed to explore this aspect. METHODS: miR-130a expression in peripheral blood mononuclear cells obtained from 50 healthy controls (HCs) at recruitment and 257 ESRD patients undergoing CAPD at month (M)0, M12, M24, and M36 was determined by reverse transcription-quantitative polymerase chain reaction. ESRD patients undergoing CAPD were followed up until MACCE occurred or M36. Then, MACCE were recorded, and MACCE-free survival was calculated. RESULTS: miR-130a expression was significantly lower in ESRD patients undergoing CAPD than in HCs (p < 0.001). In addition, miR-130a expression significantly decreased from M0 to M36 in ESRD patients undergoing CAPD (p < 0.001). Moreover, miR-130a expression at M0, M12, and M24 was significantly lower in patients with MACCE than in those without MACCE (all p < 0.05). Furthermore, high miR-130a expression at M0, M12, and M36 was significantly correlated with prolonged MACCE-free survival in ESRD patients undergoing CAPD (all p < 0.05), and high miR-130a expression at M0 was an independent factor for improved MACCE-free survival (p = 0.015; hazard ratio (HR) (95% confidential interval): 0.456 (0.243-0.857)). CONCLUSION: miR-130a expression decreases continuously with disease progression in patients with ESRD undergoing CAPD. Additionally, this expression is negatively correlated with MACCE risk in these patients.
Authors: Chih-Wei Yang; David C H Harris; Valerie A Luyckx; Masaomi Nangaku; Fan Fan Hou; Guillermo Garcia Garcia; Hasan Abu-Aisha; Abdou Niang; Laura Sola; Sakarn Bunnag; Somchai Eiam-Ong; Kriang Tungsanga; Marie Richards; Nick Richards; Bak Leong Goh; Gavin Dreyer; Rhys Evans; Henry Mzingajira; Ahmed Twahir; Mignon I McCulloch; Curie Ahn; Charlotte Osafo; Hsiang-Hao Hsu; Lianne Barnieh; Jo-Ann Donner; Marcello Tonelli Journal: Kidney Int Suppl (2011) Date: 2020-02-19
Authors: Ian A Scott; Paul Scuffham; Deepali Gupta; Tanya M Harch; John Borchi; Brent Richards Journal: Aust Health Rev Date: 2020-02 Impact factor: 1.990
Authors: Jacek Gacoń; Rafał Badacz; Ewa Stępień; Izabela Karch; Francisco J Enguita; Krzysztof Żmudka; Tadeusz Przewłocki; Anna Kabłak-Ziembicka Journal: Kardiol Pol Date: 2018-01-19 Impact factor: 3.108
Authors: Andreas Zietzer; Eva Steffen; Sven Niepmann; Philip Düsing; Mohammed Rabiul Hosen; Weiyi Liu; Paul Jamme; Baravan Al-Kassou; Philipp Roger Goody; Sebastian Zimmer; Katrin S Reiners; Alexander Pfeifer; Michael Böhm; Nikos Werner; Georg Nickenig; Felix Jansen Journal: Cardiovasc Res Date: 2022-01-07 Impact factor: 10.787